Current status of doublet combinations of platinum and fluoropyrimidines using oxaliplatin for advanced gastric cancer

Yagi, Shusuke; Yamada, Katsushi; Terayama, Mamoru; Wake, Hitomi; Enomoto, Naoki; Nohara, Kyoko; Takemura, Nobuyuki; Kiyomatsu, Tomomichi; Kokudo, Norihiro

doi:10.35772/ghm.2020.01075

Cited by 6 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 27.5% of patients in Makiyama et al’s study received a reduced initial dose of cisplatin [ 20 ], whereas all patients in Hwang et al’s study (which was set in Korea) were administered a reduced initial dose of oxaliplatin plus capecitabine (110 mg/m 2 ) [ 23 ]. In a real-world clinical setting, most elderly patients are administered reduced doses of palliative chemotherapy [ 38 , 39 ], and in Japan, the standard regimen of oxaliplatin plus S-1 is an initial dose of 100 mg/m 2 for patients with advanced gastric cancer based on the G-SOX trial [ 5 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study

et al. 2022

View full text Add to dashboard Cite

Background Whether an oxaliplatin- or cisplatin-based regimen is more optimal for treating elderly patients with advanced gastric cancer, in terms of survival and adverse events remains unclear. Methods In this retrospective cohort study, we used stacked claim data of residents in two Japanese prefectures collected between 2012 and 2017 and between 2014 and 2019, respectively. We included patients with advanced gastric cancer who received oxaliplatin-based and cisplatin-based regimens. Propensity score overlap weighting analysis was conducted to compare overall survival and granulocyte colony-stimulating factor use during chemotherapy between the oxaliplatin- and cisplatin-based treatment groups. Results A total of 242 patients were included in the study. After propensity score weighting, Kaplan–Meier analysis showed no significant differences in overall survival between the two groups (hazard ratio: 1.13; 95% confidence interval, 0.60–2.11; p = 0.70). However, the proportion of patients receiving granulocyte colony-stimulating factor was significantly lower in the oxaliplatin group than in the cisplatin group (2.3% vs.22.7%, p = 0.01). Conclusions Survival did not differ significantly between elderly patients with advanced gastric cancer treated with oxaliplatin-based versus cisplatin-based regimens; however, the oxaliplatin-based regimen was associated with less granulocyte colony-stimulating factor use.

show abstract

Section: Discussionmentioning

confidence: 99%

Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Both FP efficacy and toxicity rely on the final concentration of FUTP and FdUTP. FP efficacy as a first line or add-on therapy in different cancers is well-documented ( García-Alfonso et al, 2021 ; Yagi et al, 2021 ; Kataria et al, 2022 ; Khankhel et al, 2022 ) and will not be further discussed herein. Toxicity, however, is a serious drawback of FP therapy.…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?

2023

View full text Add to dashboard Cite

Fluoropyrimidines are chemotherapeutic agents widely used for the treatment of various solid tumors. Commonly prescribed FPs include 5-fluorouracil (5-FU) and its oral prodrugs capecitabine (CAP) and tegafur. Bioconversion of 5-FU prodrugs to 5-FU and subsequent metabolic activation of 5-FU are required for the formation of fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate, the active nucleotides through which 5-FU exerts its antimetabolite actions. A significant proportion of FP-treated patients develop severe or life-threatening, even fatal, toxicity. It is well known that FP-induced toxicity is governed by genetic factors, with dihydropyrimidine dehydrogenase (DPYD), the rate limiting enzyme in 5-FU catabolism, being currently the cornerstone of FP pharmacogenomics. DPYD-based dosing guidelines exist to guide FP chemotherapy suggesting significant dose reductions in DPYD defective patients. Accumulated evidence shows that additional variations in other genes implicated in FP pharmacokinetics and pharmacodynamics increase risk for FP toxicity, therefore taking into account more gene variations in FP dosing guidelines holds promise to improve FP pharmacotherapy. In this review we describe the current knowledge on pharmacogenomics of FP-related genes, beyond DPYD, focusing on FP toxicity risk and genetic effects on FP dose reductions. We propose that in the future, FP dosing guidelines may be expanded to include a broader ethnicity-based genetic panel as well as gene*gene and gender*gene interactions towards safer FP prescription.

show abstract

N6-methyladenosine (m6A) writer KIAA1429 accelerates gastric cancer oxaliplatin chemoresistance by targeting FOXM1

Tang

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Current status of doublet combinations of platinum and fluoropyrimidines using oxaliplatin for advanced gastric cancer

Cited by 6 publications

References 35 publications

Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study

Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?

N6-methyladenosine (m6A) writer KIAA1429 accelerates gastric cancer oxaliplatin chemoresistance by targeting FOXM1

Contact Info

Product

Resources

About